Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)Yuehong Cui, Tianshu Liu, Yian Du et al.|BMC Cancer|2023Cited by 14
Does resection after neoadjuvant chemotherapy of Docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? A multicenter, prospective cohort study (Neo-REGATTA)Yuehong Cui, Tianshu Liu, Yiyi Yu et al.|Research Square|2023Cited by 0